Cardiol Therapeutics Inc.
NASDAQ:CRDL
1.25 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Cardiol Therapeutics Inc. |
Symbool | CRDL |
Munteenheid | USD |
Prijs | 1.25 |
Beurswaarde | 102,004,250 |
Dividendpercentage | 0% |
52-weken bereik | 0.96 - 3.12 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. David G. Elsley MBA |
Website | https://www.cardiolrx.com |
An error occurred while fetching data.
Over Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)